Frontier Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Frontier Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-199,534	Closed	-$13M	–	308
2020 Q3	$13M	Buy	199,534 +31,488	+19%	+$2.06M	0.11%	196
2020 Q2	$12.3M	Sell	168,046 -30,367	-15%	-$1.62M	0.11%	196
2020 Q1	$6.75M	Buy	198,413 +2,098	+1%	+$95.9K	0.08%	218
2019 Q4	$10.7M	Buy	196,315 +107,033	+120%	+$5.3M	0.08%	218
2019 Q3	$3.73M	Buy	+89,282	New	+$3.77M	0.03%	260

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Frontier Capital Management's BHVN Position: Q4 2020 in Review

Frontier Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2020, closing a stake of 199,534 shares — an estimated $13M sold.

Frontier Capital Management first reported a position in BHVN in Q3 2019 and held it in 5 quarters. The position peaked at $13M in Q3 2020. 238 funds tracked by Wall St. Rank hold BHVN as of Q4 2020.

Frontier Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2020 after selling out during the quarter.
Frontier Capital Management sold 199,534 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2020, an estimated $13M.
Frontier Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 5 quarters.
Frontier Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $13M in Q3 2020.
238 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2020.

Based on Frontier Capital Management's 13F filing for Q4 2020, filed 19 Jan 2021.